Rycal Program

About RyCarma Therapeutics

RyCarma Therapeutics is pioneering first-in-class therapeutics targeting ryanodine receptors (RyRs), a fundamental pathway in calcium signaling implicated in serious muscle diseases. Built on decades of foundational research from founder Dr. Andrew Marks, the company's platform has produced Rycals®, small molecules designed to repair dysfunctional RyRs and modify disease progression. The company is advancing its lead candidate, Surlorian, for heart failure and has programs for RYR1-related myopathies, leveraging prior Phase 2 clinical experience with an earlier Rycal molecule. With a seasoned leadership team and an exclusive license from Columbia University, RyCarma is positioned to address high-unmet-need conditions where current treatments are largely symptomatic.

Therapeutic Areas